Biologics CDMO Market Size, Share and Forecast 2025 to 2034

Biologics CDMO Market Size is valued at USD  24.2 Bn in 2024 and is predicted to reach USD  125.5 Bn by the year 2034 at a 18.1% CAGR during the forecast period for 2025 to 2034.

Biologics CDMO Market Size, Share & Trends Analysis Report By Cell Type (Mammalian, Non-mammalian), By Product Type (Biologics (Monoclonal Antibodies, Recombinant Proteins, Antisense and Molecular Therapy, Vaccines, Other Biologics, Biosimilars), By Region, And By Segment Forecasts, 2025 to 2034

Key Industry Insights & Findings from the report:

•  The global Biologics CDMO market is poised for a significant growth, fueled by the increasing demand for biologics and biosimilars in the pharmaceutical industry.
• CDMOs are increasingly pivotal in biologics production, offering expertise and capacity to meet pharmaceutical companies' growing demand.
• Technological advancements, such as single-use bioreactors and continuous bioprocessing, are revolutionizing biologics manufacturing, enhancing efficiency, and reducing production costs.
• North America Is Expected To Grow With The Highest CAGR During The Forecast Period

Biologics Contract Development and Manufacturing Organisations (CDMOs) are essential in developing and manufacturing biopharmaceuticals, also known as biologics. These organisations provide specialised services to biopharmaceutical businesses, assisting them from the early stages of drug discovery to commercial manufacturing. Several variables influence the Biologics Contract Development and Manufacturing Organisation (CDMO) market's growth and development. These factors represent rising biologics demand, advances in biopharmaceutical technology, and the changing landscape of the pharmaceutical and biotechnology industry. The rising prevalence of complicated disorders, combined with the efficacy of biologics in treating various ailments, has increased the demand for biopharmaceuticals.

However, the COVID-19 pandemic has already had an impact on the pharmaceutical and biopharmaceutical industries, especially the Biologics CDMO (Contract Development and Manufacturing Organisation) market. The epidemic disrupted global supply chains, affecting raw materials and essential components used in biologics development. CDMOs encountered logistical, transportation, and procurement problems that hampered their ability to sustain flawless operations.

Competitive Landscape

Some Major Key Players In The Biologics CDMO Market:

• Boehringer Ingelheim Group
• Lonza Group
• Samsung Biologics
• NOVARTIS AG
• Toyobo Co. Limited
• Parexel International Corporation
• Catalent Inc.
• Binex Co. Limited
• AGC Biologics
• AbbVie Contract Manufacturing
• JRS Pharma
• Fujifilm Diosynth Biotechnologies USA Inc.
• Wuxi Biologics
• Others

Market Segmentation:

The Biologics CDMO Market is segmented on the basis of cell type and product type. According to cell type, the market is segmented as Mammalian and Non-mammalian. The product type segment includes Biologics and Biosimilars. By biologics, the market is segmented into monoclonal antibodies, recombinant proteins, antioxidant and molecular therapy, vaccines, and other biologics.

Based On Cell Type, The Mammalian Segment Is A Major Contributor To The Biologics CDMO Market. 

The Mammalian category is expected to hold a major share of the global Biologics CDMO Market in 2024. Various variables influence the Biologics Contract Development and Manufacturing Organisation (CDMO) market for mammalian cell-based processes, reflecting the increasing demand for biologics manufactured utilising mammalian cell cultures. Mammalian cells are frequently utilised to produce complicated biopharmaceuticals (monoclonal antibodies and recombinant proteins).

The growing pipeline of biopharmaceuticals, particularly those involving large and complicated compounds, needs synthesis in mammalian cell cultures. CDMOs that specialise in mammalian cell-based processes are well-positioned to help with the development and production of these sophisticated therapies.

The Monoclonal Antibodies Segment Witness Growth At A Rapid Rate.

The monoclonal antibodies segment is likely to grow rapidly in the global Biologics CDMO Market. Several factors influence the Biologics Contract Development and Manufacturing Organisation (CDMO) market, focusing on monoclonal antibodies (mAbs), reflecting the increasing need for mAb-based therapeutics. Monoclonal antibodies are commonly utilised to treat cancer, autoimmune disorders, and infectious diseases and other similar diseases. The development of several monoclonal antibody platforms, including classic and next-generation formats, broadens therapeutic intervention choices.

In The Region, The North America Biologics CDMO Market Holds A Significant Revenue Share.

The North American Biologics CDMO Market is expected to record the maximum market share in revenue in the near future due to the existence of two major economies, notably the United States and Canada. The United States has one of the world's largest pharmaceutical sectors, accounting for a sizable portion of market sales. The increasing prevalence of chronic diseases, population ageing, and the increased requirement for evidence-based practice are all factors that have contributed to the strong need for clinical trials in the United States.

In recent years, the location of clinical trials has migrated from academic medical centres to community-based practises to worldwide venues in various countries. Moreover, the Asia Pacific biopharmaceutical sector is expanding rapidly, owing to rising healthcare costs, the frequency of chronic diseases, and scientific developments. This expansion presents the potential for Biologics CDMOs to support biologics development and manufacture.

Recent Developments:

• In April 2023, Lonza entered into a partnership with ABL Bio, a company specializing in the development of bispecific antibodies for the treatment of immuno-oncology and neurological illnesses.     The purpose of the agreement was to facilitate the advancement and production of ABL Bio's novel bispecific antibody product. 

• In April 2022, ChimeronBio established a manufacturing collaboration with FUJIFILM Diosynth Biotechnologies (FDB) in order to expand its Oncology portfolio to encompass clinics. ChimeronBio chose FUJIFILM Diosynth Biotechnologies as its partner in the transfer and scalability of its medicinal substance manufacturing method.

Biologics CDMO Market Report Scope